Explore how genetics may influence the effectiveness of GLP-1 medications in children with obesity, and what personalized treatment means for the future.

Today’s post carries on from “The Nutrition That Never Arrived,” which discusses the work of Dr. Dhruv Khullar, as well as a study of ultra-processed foods.

Learn how GLP-1 medications are transforming childhood obesity treatment, including benefits, risks, and access challenges for families.

A ton of money was being spent to repair the ravages of BPA on kids, and on young people and adults who had encountered it in early life.

Childhood obesity may limit future income and mobility. Learn how early health impacts education, careers, and the American Dream.

Check out that headline: “Why Is the American Diet So Deadly?” The adjective isn’t “detrimental” or even “dangerous,” but a much more loaded d-word: deadly.

New research shows reducing parent stress may help prevent childhood obesity. Learn how mindfulness and positive parenting support healthier kids.

As society operates today, high weight status coexists with low societal status and low economic status, and quite often with racial minority status.

CDC data show 21.1% of U.S. children have obesity — a record high. Experts warn of rising risks and call for urgent prevention and treatment efforts.

Caregivers’ trust, values, and food insecurity shape decisions about GLP-1 medications for children with obesity, highlighting need for shared decision-making.

FDA approves the first Wegovy weight loss pill, offering an oral GLP-1 alternative with results similar to injections.

New research reveals how gut microbes send metabolites to the liver and heart, shaping insulin sensitivity and metabolism linked to obesity and type 2 diabetes.

A global review of 177 studies reveals key early-life factors driving childhood obesity, highlighting risks, research gaps, and opportunities for prevention.

GLP-1 drugs are reshaping diabetes and weight-loss care. Here’s how new treatments, pricing shifts, and coverage decisions impact employer health plans.

While learning about dissociative identity disorder, psychiatry found that there might be more than one alternative personality along with the original.

When it comes to kids and GLP-1s, careful consideration is just as vital as clinical innovation.

U.S. obesity rates drop as GLP-1 drugs like Ozempic and Wegovy surge, but diabetes hits a record high, new Gallup data shows.

Penn State researchers are using AI to track how quickly kids eat — a key factor linked to childhood obesity risk.

Learn how evidence-based treatments like semaglutide, tirzepatide, and GLP-1 receptor agonists are reshaping adult and pediatric obesity care.

Childhood obesity in Europe is rising. Experts debate GLP-1 drugs for kids: balancing safety, access, and prevention in tackling this epidemic.

New study shows Mounjaro lowers blood sugar and BMI in kids with Type 2 diabetes, paving the way for FDA approval in younger patients.

Yale study finds 20–40% of obesity-related conditions in U.S. youth are tied to obesity, highlighting the importance of early prevention and treatment.

A new brain-targeted obesity drug may offer weight loss without GLP-1 side effects, using support cells to curb appetite and improve glucose control.

New research reveals that approximately 17 million adolescents and young adults in the U.S. meet the criteria for GLP-1RA therapy, but it’s complicated.

A new study using genetic data from over 5 million people has developed a powerful polygenic risk score that predicts childhood obesity risk.

Obesity is a very, very expensive condition, and the more assiduously the logisticians examine the problem, the more frightening it becomes.

New study: Prenatal and early-life conditions significantly shape a child’s risk for obesity later in life.

A clinical trial showed that this monthly injection could change the game, especially for those who struggle with weekly dosing.

It is possible to encourage one’s personal stock of the helpful bacterium by eating its favorite foods, like high-fiber vegetation and nondigestible carbs.

Despite the long-term nature of obesity, current clinical guidelines are usually split into rigid age categories. Some experts say it needs to change.